Evidence map›Paper›PMID 34211459›Full record

ReviewFrontiers in immunology2021

Cytoreductive Nephrectomy Promoted Abscopal Effect of Camrelizumab Combined With Radiotherapy for Metastatic Renal Cell Carcinoma: A Case Report and Review of the Literature.

Min Wu, Jie Liu, Samuel Seery, Xue Meng, Jinbo Yue

Open access · goldAbstract readCase ReportsReview
In one paragraph

Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Min WuCheeloo College of Medicine, Shandong University, Jinan, China.
Jie LiuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Samuel SeeryHealth Research, Faculty of Health and Medicine, Lancaster University, City of Lancaster, United Kingdom.
Xue MengCheeloo College of Medicine, Shandong University, Jinan, China.
Jinbo YueCheeloo College of Medicine, Shandong University, Jinan, China.
Shandong First Medical University · CNLancaster University · GBShandong Tumor Hospital · CNShandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is little evidence around Camrelizumab combined with cytoreductive nephrectomy (CN) and radiotherapy (RT) as a treatment option for metastatic renal cell carcinoma (mRCC). The influence of CN on immune responses and the abscopal effect are not well understood. In this paper, we report a case of anti-programmed cell death-1 (PD-1) treated with combined RT once CN reduced the primary tumor burden (TB). This patient also encountered an increased response to targeted radiotherapy after immune resistance. We also observed a macrophage-to-lymphocyte ratio (MLR) peak, which may be correlated with subsequent pseudoprogression after thoracic radiotherapy. Consequently, even with the disease, this patient has remained stable. This peculiar instance suggests there is a need to investigate the underlying mechanisms of CN in promoting the abscopal effect during immunotherapy when combined with RT. It also suggests that there is a need for further investigation into the role of RT in overcoming immune resistance, and the value of MLR in predicting pseudoprogression. We hypothesize that a heavy tumor burden might suppress the abscopal effect, thereby ensuring that CN promotes it. However, radiotherapy may overcome immune resistance during oligoprogression.

Indexed as

AgedAntibodies, Monoclonal, HumanizedCarcinoma, Renal CellCombined Modality TherapyCytoreduction Surgical ProceduresHumansImmune Checkpoint InhibitorsKidney NeoplasmsLymphocyte Culture Test, MixedMaleNeoplasm MetastasisNephrectomyRadiotherapy DosageReceptors, Antigen, T-Cell, alpha-betaTumor-Associated MacrophagesAntibodies, Monoclonal, HumanizedcamrelizumabImmune Checkpoint InhibitorsReceptors, Antigen, T-Cell, alpha-betaabscopal effectcamrelizumabclear cell renal cell carcinomaMLRpseudoprogression

Identifiers

PMID34211459
PMCPMC8239433
OpenAlexW3166340799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.